Here are five things to know:
1. On Feb. 15, six analysts gave the shares a “strong buy” rating and three analysts gave the shares a “buy” rating.
2. Six analysts gave the shares a “neutral” rating.
3. Integra LifeSciences Holdings has a 50-day moving average of $62.57 and 200-day moving average of $62.29.
4. The market cap is $2.05 billion.
5. During the last trading session, the shares were down 0.07 percent.
More articles on devices:
ConforMIS reports Q4, full year results — 12 things to know
Hip, knee orthopedic surgical implants market to reach $33M by 2022: 3 takeaways
National Government Services establishes positive coverage for MIS SI joint fusion: 5 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
